Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Icosapent ethyl is a highly purified formulation of eicosapentaenoic acid, a type of omega-3 fatty acid contained in fish oil. While omega-3 fatty acids have long been thought to have cardioprotective benefits, the Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) has helped to establish icosapent ethyl as an evidence-based therapy for risk reduction of atherosclerotic cardiovascular disease (ASCVD). REDUCE-IT, however, was by no means an overnight success story. Close examination of the evidence shows that the trial was a culmination of many lessons learned from previous studies. The purpose of this manuscript is to review contemporary evidence of icosapent ethyl in ASCVD risk reduction and the clinical implication of this promising therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It remains unclear as to why these differences exist and brings to the fore the hypothesis that triglycerideindependent effects of EPA may be in part responsible for the CV benefits seen in the REDUCE-IT trial”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Üstün, Y. E. (2019) · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · Cited by 169,581
Home visits: a strategy to improve newborn survival - Authors' reply
(2008) · Americanae (AECID Library) · doi:10.1016/s0140 · Cited by 22,524
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317 · cited 2×
“98).(35) There was actually a lower rate of gastrointestinal adverse events, though this may be attributable to the use of mineral oil as the placebo.”
BackgroundResult(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284 · cited 1×
“pies such as fibrates and niacin have not shown to improve cardiovascular outcomes.(8,9) EPA Effects on Lipids, Lipoproteins and Markers of Inflammation Omega-3 FA agents are known to reduce TGs and have been used for the treatment of hypertriglyceridemia.”
BackgroundPro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041 · cited 1×
“SPMs play an important role in counter-regulation of inflammation including in atherosclerosis.(29,30) When”
BackgroundEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 1×
“pies such as fibrates and niacin have not shown to improve cardiovascular outcomes.(8,9) EPA Effects on Lipids, Lipoproteins and Markers of Inflammation Omega-3 FA agents are known to reduce TGs and have been used for the treatment of hypertriglyceridemia.”
BackgroundYokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516 · cited 2×
“0001), including higher rates of abnormal laboratory data, gastrointestinal disturbances, dermatologic side effects and bleeding.(33) Conversely, serious adverse events were observed to be similar between icosapent ethyl and placebo in REDUCE-IT (30.”
Background(1999) · PubMed · Cited by 2,062
Omega-3 Fatty Acids and Cardiovascular Disease
Mozaffarian, D., & Wu, J. H. Y. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.063 · Cited by 1,771 · cited 4×
“EPA and DHA lower serum TGs in a dose- dependent manner, with higher doses (3 to 4 g/day) leading to higher reductions in TGs.4 Mendelian rando- mization studies suggest that triglyceride-rich lipopro- teins, especially very low-density lipoprotein (VLDL) and their remnants, are causally associated with atheroscleroti…”
BackgroundInfluentialGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Wall, R., Ross, R. P., Fitzgerald, G. F., & Stanton, C. (2010) · Nutrition Reviews · doi:10.1111/j.1753-4887.2010.00287.x · Cited by 1,101 · cited 1×
“inflammatory properties as opposed to omega-6 derived eicosanoids derived from arachidonic acid.(28) EPA also”
BackgroundLoss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
Manson, J. E., Cook, N. R., Lee, I.-M., Christen, W., Bassuk, S. S., Mora, S., Gibson, H., Albert, C. M., Gordon, D., Copeland, T., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811403 · Cited by 979 · cited 1×
“90).(50) There are several potential reasons why EPA trials have more consistently shown cardioprotective effects on outcomes compared with trials using EPA plus DHA beyond Jia et al Dovepress”
Resultn–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936 · cited 1×
“93).(46) Finally, the OMEGA trial showed no difference in sudden cardiac death at 1 year in survivors of acute MI randomized to 900 mg of n-3 PUFA versus placebo (1.”
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929 · cited 1×
“81).(45) The Alpha Omega trial randomized 4,837 patients with a history of MI within 10 years of randomization to 400 mg daily of EPA and DHA, 2 g daily of alpha-linolenic acid (ALA), both, or placebo over 40 months.”
MethodCommon variants associated with plasma triglycerides and risk for coronary artery disease
Do, R., Willer, C. J., Schmidt, E. M., Sengupta, S., Gao, C., Peloso, G. M., Gustafsson, S., Kanoni, S., Ganna, A., Chen, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2795 · Cited by 862
Impact of Omega-3 Fatty Acids on the Gut Microbiota
Costantini, L., Molinari, R., Farinon, B., & Merendino, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122645 · Cited by 741 · cited 1×
“different effect on gut microbiota by different dietary oils, which can, in turn, impact the expression of inflammatory mediators.(39,40) It is unclear whether mineral oil may shift the gut microbiome towards a more pro-inflammatory”
BackgroundTriglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60545-4 · Cited by 716
Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698 · cited 1×
“4 years.(49) The VITAL study also did not show a benefit from n-3 PUFA therapy (daily intake of 1g capsule containing 460mg EPA and 380mg DHA) in primary prevention of cardiovascular events (3.”
BackgroundRauch, B., Schiele, R., Schneider, S., Diller, F., Victor, N., Gohlke, H., Gottwik, M., Steinbeck, G., Del Castillo, U., Sack, R., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.948562 · Cited by 607 · cited 1×
“84).(47) With respect to primary prevention, the Risk and Prevention Study Collaborative Group randomized n-3 PUFA 1 g daily to placebo of olive oil in patients with multiple cardiovascular risk factors or ASCVD without prior myocardial infarction, but n-3 PUFA did not reduce cardiovascular morbidity and mortality com…”
BackgroundLeaf, A., Kang, J. X., Xiao, Y.-F., & Billman, G. E. (2003) · Circulation · doi:10.1161/01.cir.0000069566.78305.33 · Cited by 605
n–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors
The Risk and Prevention Study Collaborative Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205409 · Cited by 510 · cited 1×
“With respect to primary prevention, the Risk and Prevention Study Collaborative Group randomized n-3 PUFA 1 g daily to placebo of olive oil in patients with multiple cardiovascular risk factors or ASCVD without prior myocardial infarction, but n-3 PUFA did not reduce cardiovascular morbidity and mortality compared to…”
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s010 · Cited by 471
Fredman, G., Hellmann, J., Proto, J. D., Kuriakose, G., Colas, R. A., Dorweiler, B., Connolly, E. S., Solomon, R., Jones, D. M., Heyer, E. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms12859 · Cited by 411 · cited 1×
“SPMs play an important role in counter-regulation of inflammation including in atherosclerosis.(29,30) When”
BackgroundBarreto, M. L., Teixeira, M. G., Bastos, F. I., Ximenes, R. A., Barata, R. B., & Rodrigues, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60202-x · Cited by 396
Bays, H. E., Ballantyne, C. M., Kastelein, J. J., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.04.015 · Cited by 358
Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Stein, E., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.05.031 · Cited by 342
Saito, Y., Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.06.003 · Cited by 316
Fish oil — How does it reduce plasma triglycerides?
Shearer, G. C., Savinova, O. V., & Harris, W. S. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.011 · Cited by 285 · cited 1×
“Both EPA and DHA reduce hepatic VLDL-TG production via interference of non-esterified fatty acid influx into the liver.(22) Omega-3 FAs are also thought to prevent VLDL assembly and secretion by promoting degradation of apoB100 and upregulating betaoxidation of free fatty acid in hepatocytes, resulting in a decrease i…”
BackgroundJacobson, T. A., Glickstein, S. B., Rowe, J. D., & Soni, P. N. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.10.018 · Cited by 263 · cited 1×
“previous studies found that DHA may increase LDL-C levels while EPA did not.(10) One important rationale for using”
BackgroundEffects of Icosapent Ethyl on Total Ischemic Events
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.032 · Cited by 259 · cited 1×
“endpoint event but also reduced the risk for developing subsequent major cardiovascular events.(37) The relative”
BackgroundCawood, A. L., Ding, R., Napper, F. L., Young, R. H., Williams, J. A., Ward, M. J. A., Gudmundsen, O., Vige, R., Payne, S. P. K., Ye, S., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.022 · Cited by 243
Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
Ganda, O. P., Bhatt, D. L., Mason, R. P., Miller, M., & Boden, W. E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.061 · Cited by 195 · cited 1×
“8g/day in secondary prevention of ASCVD events among 3,900 Japanese patients with stable coronary artery disease.(59,60) Meanwhile, the Statin Residual Risk Reduction with EpaNova in High Cardiovascular Risk (STRENGTH) trial will assess the efficacy and safety of EPA +DHA carboxylic acid at 4g/day vs placebo (corn oil…”
BackgroundMason, R. P., Jacob, R. F., Shrivastava, S., Sherratt, S. C. R., & Chattopadhyay, A. (2016) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2016.10.002 · Cited by 179 · cited 1×
“which in turn imparts a protective effect against endothelial dysfunction.(31) Moreover, higher concentration of EPA”
BackgroundNicholls, S. J., Lincoff, A. M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., Mozaffarian, D., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23055 · Cited by 167 · cited 2×
“The Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy – Statin and Eicosapentaenoic Acid (RESPECT-EPA) aims to assess the efficacy and safety of EPA 1.8g/day in secondary prevention of ASCVD events among 3,900 Japanese patients with stable coronary artery disease.59,60 Meanwhile,…”
MethodSurprises from genetic analyses of lipid risk factors for atherosclerosis
Musunuru, K., & Kathiresan, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306398 · Cited by 159
Mita, T., Watada, H., Ogihara, T., Nomiyama, T., Ogawa, O., Kinoshita, J., Shimizu, T., Hirose, T., Tanaka, Y., & Kawamori, R. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.03.005 · Cited by 153 · cited 1×
“Studies have shown that treatment with EPA resulted reduction in the progression of carotid intima-media thickness and stabilization of vulnerable coronary plaques.(20,21)”
BackgroundBerge, R. K., Madsen, L., Vaagenes, H., Tronstad, K. J., Göttlicher, M., & Rustan, A. C. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3430191 · Cited by 148 · cited 4×
“EPA and DHA lower serum TGs in a dose- dependent manner, with higher doses (3 to 4 g/day) leading to higher reductions in TGs.4 Mendelian rando- mization studies suggest that triglyceride-rich lipopro- teins, especially very low-density lipoprotein (VLDL) and their remnants, are causally associated with atheroscleroti…”
BackgroundInfluentialMyocardial membrane fatty acids and the antiarrhythmic actions of dietary fish oil in animal models
McLennan, P. L. (2001) · Lipids · doi:10.1007/s11745-001-0692-x · Cited by 147
Khan, S., Minihane, A.-M., Talmud, P. J., Wright, J. W., Murphy, M. C., Williams, C. M., & Griffin, B. A. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30473-9 · Cited by 145
Bays, H. E., Ballantyne, C. M., Braeckman, R. A., Stirtan, W. G., & Soni, P. N. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-012-0002-3 · Cited by 141
Regulatory activity of polyunsaturated fatty acids in T-cell signaling
Kim, W., Khan, N. A., McMurray, D. N., Prior, I. A., Wang, N., & Chapkin, R. S. (2010) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.01.002 · Cited by 138
Nishio, R., Shinke, T., Otake, H., Nakagawa, M., Nagoshi, R., Inoue, T., Kozuki, A., Hariki, H., Osue, T., Taniguchi, Y., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.02.025 · Cited by 133
Fish oil fatty acids impair VLDL assembly and/or secretion by cultured rat hepatocytes.
Lang, C., & Davis, R. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42272-2 · Cited by 116
Orringer, C. E., Jacobson, T. A., & Maki, K. C. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.10.014 · Cited by 103 · cited 1×
“Scientific statement from the NLA also recommends the use of icosapent ethyl in patients with clinical ASCVD, or with diabetes mellitus plus ≥1 addition risk factor with hypertriglyceridemia and on maximally tolerated statin therapy (Class I; evidence B-R).(53) While the use of icosapent ethyl for ASCVD risk reduction…”
MethodNosaka, K., Miyoshi, T., Iwamoto, M., Kajiya, M., Okawa, K., Tsukuda, S., Yokohama, F., Sogo, M., Nishibe, T., Matsuo, N., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.105 · Cited by 88 · cited 1×
“04).(34) Building upon the findings of the previous trials, REDUCE-IT was a multi-centered, double-blinded, randomized placebo-controlled trial of 8,179 participants evaluating the efficacy and safety of icosapent ethyl 2g twice daily compared to mineral oil as placebo.”
ResultClarke, S. D., Turini, M. E., & Jump, D. Β. (1997) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(97)90494-4 · Cited by 74
Brinton, E. A., Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Braeckman, R. A., & Soni, P. N. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-100 · Cited by 70
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The University of North Carolina at Chapel Hill University Libraries (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/tchk-ac83 · Cited by 60
Miller, M. J., Ballantyne, C. M., Bays, H. E., Granowitz, C. B., Doyle, R. T., Juliano, R. A., & Philip, S. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.05.057 · Cited by 52
Ballantyne, C. M., Bays, H. E., Braeckman, R. A., Philip, S., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.02.008 · Cited by 47
Patrone, V., Minuti, A., Lizier, M., Miragoli, F., Lucchini, F., Trevisi, E., Rossi, F., & Callegari, M. L. (2018) · BMC Genomics · doi:10.1186/s12864-018-5202-z · Cited by 47 · cited 1×
“different effect on gut microbiota by different dietary oils, which can, in turn, impact the expression of inflammatory mediators.(39,40) It is unclear whether mineral oil may shift the gut microbiome towards a more pro-inflammatory”
BackgroundBallantyne, C. M., Braeckman, R. A., Bays, H. E., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.11.009 · Cited by 46
Bays, H. E., Ballantyne, C. M., Doyle, R. T., Juliano, R. A., & Philip, S. (2016) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2016.07.007 · Cited by 43 · cited 1×
“8g daily dose in the Japanese population in JELIS due to very high background dietary intake of omega-3 fatty acids in the latter.(36) Individuals included in REDUCE-IT had either established ASCVD or diabetes mellitus with additional ASCVD risk factors, had elevated fasting TG levels but relatively well-controlled LD…”
BackgroundPark, Y., Jones, P. G., & Harris, W. S. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.1.45 · Cited by 41
Omega-3 fatty acid and cardiovascular outcomes: insights from recent clinical trials
Jia, X., Kohli, P., & Virani, S. S. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0763-0 · Cited by 39 · cited 3×
“The degree of increase in LDL-C and hs-CRP observed in the placebo group compared to the icosapent ethyl group, however, is unlikely to fully account for the risk reduction in ASCVD outcomes for patients treated with EPA.41 Vascular Health and Risk Management 2020:16 submit your manuscript | www.dovepress.com DovePres…”
BackgroundInfluentialSelf-citationLaake, K., Myhre, P., Nordby, L. M., Seljeflot, I., Abdelnoor, M., Smith, P., Tveit, A., Arnesen, H., & Solheim, S. (2014) · BMC Geriatrics · doi:10.1186/1471-2318-14-74 · Cited by 31
Ballantyne, C. M., Manku, M. S., Bays, H. E., Philip, S., Granowitz, C. B., Doyle, R. T., & Juliano, R. A. (2019) · Cardiology and Therapy · doi:10.1007/s40119-019-0131-8 · Cited by 24
Kodera, S., Morita, H., Kiyosue, A., Ando, J., & Komuro, I. (2018) · Circulation Journal · doi:10.1253/circj.cj-17-0995 · Cited by 21 · cited 1×
“8g/day in Japanese patients with hypercholesterolemia, based on the JELIS study, found that a combination of EPA with statins had acceptable cost-effectiveness in secondary prevention but not in primary prevention.(57) The Institute for Clinical and Economic Review (ICER) also conducted a costeffectiveness analysis ba…”
MethodEligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial
Jia, X., Akeroyd, J. M., Nasir, K., Nambi, V., Ballantyne, C. M., Petersen, L. A., & Virani, S. S. (2019) · Circulation · doi:10.1161/circulationaha.118.038691 · Cited by 21 · cited 1×
“1% of high-risk diabetes patients would be eligible for icosapent ethyl within the Veterans Affairs healthcare system.(55) Analysis from the National Health and Nutrition Examination Survey (NHANES) estimates that 2.”
BackgroundSelf-citationMarine n-3 fatty acids and prevention of cardiovascular disease and cancer
Manson, J. E., Cook, N. R., Lee, I.-M. M., Christen, W. G., Bassuk, S. S., Mora, S., Gibson, H. L., Albert, C. M., Gordon, D., Copeland, T., et al. (2019) · Yearbook of pediatric endocrinology · doi:10.1530/ey.16.12.13 · Cited by 12
n-3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors
(2013) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2013.07.030 · Cited by 10
Baum, S. J. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.11.035 · Cited by 6 · cited 1×
“It is thought that the use of mineral oil as placebo may decrease the absorption of medications including statins and adversely affect the lipid profile and inflammatory markers.(38) Beyond potential effects on direct absorption”
BackgroundKhera, R., Elizondo, J. V., Saxena, A., Virani, S. S., Krumholz, H. M., & Nasir, K. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/466649 · Cited by 6 · cited 1×
“9 million individuals from the United States would potentially be candidates for icosapent ethyl, resulting in an estimated cost to the US healthcare system of almost $9 billion dollars.(56) Although there will be substantial upfront cost for icosapent ethyl, the ASCVD risk reduction conferred may make overall cost-ef…”
BackgroundSelf-citation
Research works printed but not linked: 2
- [58]Institute for Clinical and Economic Review. Additive Therapies for Cardiovascular Disease: Effectiveness and Value; 2019 Available from: https://icer-review.org/wp-content/uploads/2019/02/ICER_CVD_Draft_Evidence_Report_072419.pdf. Accessed December 2, 2019.
- [60]UMIN-CTR Clinical Trial. Randomized trial for evaluation in secondary prevention efficacy of combination therapy — statin and eicosapentaenoic acid UMIN000012069; 2018. Available from: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014051. Accessed November 22, 2019. 38873793
Cited by
Chapman, M. J., Zamorano, J. L., & Parhofer, K. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108172 · Cited by 67
Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids
Weinberg, R. L., Brook, R. D., Rubenfire, M., & Eagle, K. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.060 · Cited by 63
Triglycerides and ASCVD risk reduction: recent insights and future directions
Hussain, A., Ballantyne, C. M., Saeed, A., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00846-8 · Cited by 57
Self-citationRegular use of fish oil supplements and course of cardiovascular diseases: prospective cohort study
Chen, G., Qian, Z. M., Zhang, J., Zhang, S., Zhang, Z., Vaughn, M. G., Aaron, H. E., Wang, C., Lip, G. Y. H., & Lin, H. (2024) · BMJ Medicine · doi:10.1136/bmjmed-2022-000451 · Cited by 51
“31 No proven biological mechanism for this explanation exists, however, and the dose and formulation of omega 3 fatty acids used in clinical practice are not known.”
BackgroundThe multidimensional benefits of eicosapentaenoic acid: from heart health to inflammatory control
Nassar, M., Jaffery, A., Ibrahim, B., Baraka, B., & Abosheaishaa, H. M. (2023) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-023-00265-6 · Cited by 26
Metadata
- Authors
- Jia, X., Koh, S., Al Rifai, M., Blumenthal, R. S., & Virani, S. S.
- Affiliations
- Baylor College of Medicine (US)
- Johns Hopkins University (US)
- Michael E. DeBakey VA Medical Center (US)
- Corresponding author
- Virani, Salim S
- Venue
- Vascular Health and Risk Management
- Publisher
- Informa UK Limited
- Published
- 2020-01
- Volume
- Volume 16
- Pages
- 1-10
- ISSN
- 1176-6344 (ISSN-L)
- 1178-2048
- PMC
- PMC6957107
- OpenAlex
- W3000366026
- Cited by
- 14
- References
- 69
- Citations by year
- 2024: 3 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 5
- FWCI
- 0.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Vascular Health and Risk Management (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (acceptedVersion)
- eCommons - AKU (Aga Khan University) (submittedVersion, cc-by-nc)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Keywords
- icosapent ethyl, eicosapentaenoic acid, omega-3 fatty acids, fish oil, atherosclerotic cardiovascular disease, cardiovascular risk reduction, REDUCE-IT trial, cardioprotection
- MeSH terms
- Animals, Cardiovascular Diseases, Humans, Risk Factors, Eicosapentaenoic Acid, Risk Assessment, Evidence-Based Medicine, Dietary Supplements, Protective Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.